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Racial disparities in clinic attendance may contribute to racial disparities in plasma human immunodeficiency
virus type 1 (HIV-1) RNA levels among HIV-positive patients in care. Data from 946 African American and 535
Caucasian patients receiving HIV care at the University of North Carolina Center for AIDS Research HIV clinic be-
tween January 1, 1999, and August 1, 2012, were used to estimate the association between African American race
and HIV virological suppression (i.e., undetectable HIV-1 RNA) when racial disparities in clinic attendance were
lessened. Clinic attendance was measured as the proportion of scheduled clinic appointments attended (i.e.,
visit adherence) or the proportion of six 4-month intervals with at least 1 attended scheduled clinic appointment
(i.e., visit constancy). In analyses accounting for patient characteristics, the risk ratio for achieving suppression
when comparing African Americans with Caucasians was 0.91 (95% confidence interval: 0.85, 0.98). Lessening
disparities in adherence or constancy lowered disparities in virological suppression by up to 44.4% and 11.1%,
respectively. Interventions that lessen disparities in adherence may be more effective in eliminating disparities in
suppression than interventions that lessen disparities in constancy. Given that gaps in care were limited to be no
more than 2 years for both attendance measures, the impact of lessening disparities in adherence may be
overstated.
clinic visits; cohort studies; health status disparities; human immunodeficiency virus; viral load
Abbreviations: ART, antiretroviral therapy; CFAR, Center for AIDS Research; HIV, human immunodeficiency virus; HIV-1, human
immunodeficiency virus type 1; UAB, University of Alabama at Birmingham; UNC, University of North Carolina.
Human immunodeficiency virus (HIV)–positive African
Americans in care are more likely than Caucasians to miss
scheduled clinic appointments (1–4) and less likely than
Caucasians to suppress plasma human immunodeficiency
virus type 1 (HIV-1) RNA levels while on antiretroviral
therapy (ART) (4, 5). Contextual and behavioral factors
likely contribute to less frequent scheduled clinic attendance
among African Americans (4). Missing scheduled clinic ap-
pointments may inhibit the receipt and timely modification
of, as well as adherence to, ART among African Americans.
Using data from the University of Alabama at Birmingham
(UAB) 1917 Clinic Cohort, Mugavero et al. (4) demonstrated
that the proportion of scheduled appointments that were
missed partially explained observed racial disparities in viro-
logical response (i.e., plasma HIV-1 RNA level).
Mugavero et al. (6), however, later noted that, as a measure
of clinic attendance and in turn engagement in care, the pro-
portion of scheduled visits that were missed is limited among
patients who have gaps in care and therefore do not have
scheduled appointments to miss. Visit constancy, which re-
flects how regularly a patient receives care, is an alternative
measure of engagement for etiological research that better
captures clinic attendance among those with gaps in care.
Visit constancy has also been shown to be associated with
achieving an undetectable HIV-1 RNA level (i.e., virological
suppression) (7).
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Even in the absence of gaps in care, prior work (4) may
underestimate the extent to which the association between
race and virological response remains when disparities in
clinic attendance are lessened or induce selection bias in es-
timating this extent by conditioning on common causes of
clinic attendance and virological response that are likely in-
fluenced by race. Selection bias could be induced in the
presence of an unmeasured factor that determines the mea-
sured common causes and virological response. Such un-
derestimation or bias can be minimized with the use of
inverse probability weighting (8, 9). Here, we use inverse
probability weighted models, as well as data from 946 Afri-
can American and 535 Caucasian patients in the University
of North Carolina (UNC) Center for AIDS Research
(CFAR) HIV clinical cohort to estimate the association be-
tween African American race and virological suppression
when racial disparities in scheduled appointment adherence
and visit constancy are lessened. To be consistent with the
causal mediation analysis literature, we henceforth refer to
this association as the direct effect or the controlled direct
effect (8, 10, 11).
METHODS
Study population
The UNC CFAR HIV clinical cohort (henceforth, the co-
hort) collects sociodemographic, psychosocial, and clinical
information from all HIV-positive patients who provided
written informed consent in English or Spanish and received
care at the UNC HIV clinic. All study forms were approved
by the UNC institutional review board. Additional details
concerning this clinic cohort are provided elsewhere (12).
As shown in Figure 1, data were ascertained on 3,275 en-
rolled patients with a clinic appointment (i.e., scheduled or
walk-in) in the UNC HIV clinic during the study period, Jan-
uary 1, 1999, through August 1, 2012. The first clinic visit
was defined as the first attended appointment (i.e., scheduled
or walk-in) that occurred within the study period. Among
these 3,275 patients, 43 were excluded because they did
not have a first clinic visit, and another 114 were excluded
because they did not have an “attended” or “no show” sched-
uled clinic appointment in the UNCHIV clinic within 2 years
of their first clinic visit dates. Of the remaining 3,118 patients,
314 were excluded because they were not African American
or Caucasian or their race was unknown. Among the remain-
ing 2,804 patients, the following were also excluded: 118 pa-
tients (4%) because of the absence of information on 1 or
more characteristics at the first clinic visit; 177 patients (7%)
because of reaching August 1, 2012, prior to 2 years after
their first clinic visits; 168 patients (6%) because of dying
prior to 2 years after their first clinic visits; and 860 patients
(37%) because of the absence of any RNA assessments in the
window of 2–3 years after their first clinic visits. As described
below, measured differences between the 1,481 included pa-
tients (53% of the 2,804) and 860 of the excluded patients
(31% of the 2,804) were accounted for by using inverse prob-
ability weights (13). Inverse probability weights were not
used to account for differences between those included and
the other 463 excluded patients (16% of the 2,804) because
of the absence of information necessary to estimate inverse
probability weights or a small percent excluded.
Theoretical framework
Figure 2 shows a causal diagram for the influence of Afri-
can American race on virological suppression in the 2–3
years after the first clinic visit as mediated by clinic atten-
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Figure 1. Exclusion criteria applied to identify the 1,481 human im-
munodeficiency virus (HIV)–infected patients whowere included in the
analysis sample, University of North Carolina Center for AIDS Re-
search HIV clinical cohort, 1999–2012. The numbers of patients
who died and remained alive among the 1,481 included patients dur-
ing the 1,456 person-years of follow-up that occurred during the win-
dow of 2–3 years after their first clinic visit are also included.
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HIV-positive patients in the cohort. In our conceptual model,
and described in detail by Jones (14), race is considered to be
a socially constructed classification that measures a combina-
tion of factors including genes, social class, and culture. Af-
rican American race is thought to have direct and indirect
influences on virological suppression in the 2–3 years after
the first clinic visit. In this analysis, the indirect influence
(i.e., indirect effect) is hypothesized to operate through clinic
attendance in the first 2 years after the first clinic visit,
whereas the direct influence (i.e., controlled direct effect)
may operate through patient characteristics such as age, dis-
ease stage, mental health, alcohol and drug abuse, education,
ART use/adherence, and health insurance status at the first
and subsequent clinic visits. Note that our “direct” and “indi-
rect” labeling is based on clinic attendance being the mediat-
ing pathway of interest. The Figure 2 causal diagram was
informed by prior literature (1–4, 12, 15–22).
Assessment of race, attendance, and other patient
characteristics
Data on race were obtained from patient medical records.
In terms of the mediating pathway of interest, the 2 measures
of clinic attendance used in this analysis were the proportion
of scheduled clinic appointments attended by a given patient
(i.e., visit adherence) and the proportion of six 4-month time
intervals in which a given patient attended at least 1 scheduled
clinic appointment (i.e., visit constancy). Six 4-month time
intervals for the constancy measure were selected to be con-
sistent with prior work (7). Both measures of clinic atten-
dance had 4 levels where cut points were defined on the basis
of quartiles. However, given the distribution of the atten-
dance data, 25% of patients could not always be included in
a given attendance category. Quartiles were used, rather than
continuous attendance measures, to facilitate the construction
of stable inverse probability weights as described below.
Appointments included all scheduled clinic appointments
with primary HIV health care providers that occurred in the 2
years after the first clinic visit between January 1, 1999, and
August 1, 2012. As done previously (4, 7, 23), only sched-
uled appointments were used to assess constancy. In addi-
tion, we excluded from analysis scheduled appointments
that were canceled or rescheduled by the patient or provider,
as well as scheduled urgent care or subspecialty appoint-
ments (e.g., dermatology). Walk-in visits were also excluded
from the definition of a scheduled appointment. A 2-year as-
sessment window for clinic attendance was selected to be
consistent with prior work (4) and to allow for gaps in care
(i.e., no attended scheduled appointment for at least 1 year)
when examining whether inference changed on the basis of
the measure of clinic attendance. Information on patient char-
acteristics at the first clinic visit, such as date of birth, calendar
date, sex, CD4 cell count, clinical acquired immune deficiency
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Figure 2. Causal diagram for the influence of African American race on virological suppression, University of North Carolina Center for AIDS
Research HIV clinical cohort, 1999–2012. Boxes represent conditioning.
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mental illness diagnoses, and history of drug or alcohol abuse
was also obtained from patient medical records.
Ascertainment of virological suppression
The primary outcome of interest in this analysis was a re-
peated measure and corresponded to achieving virological
suppression at a given HIV-1 RNA assessment 2–3 years
after the first clinic visit. The 2- to 3-year interval was se-
lected to ensure appropriate temporal ordering between
race, attendance in the first 2 years, and virological suppres-
sion while allowing for the estimation of more recent effects
of attendance in the first 2 years on virological suppression.
To harmonize HIV-1 RNA data across time, we set all RNA
values of less than 400 copies/mL to 200 copies/mL and re-
garded them as undetectable. Virological suppression was
defined as achieving undetectable plasma HIV RNA (i.e.,
≤200 copies/mL) at a given RNA level assessment. Patients
were not required to have previously initiated ART for a
given RNA level assessment to be included in the analysis.
Among the 1,481 study participants, patients were cen-
sored at the minimum of their death dates (if applicable), Au-
gust 1, 2012, or 3 years after their first clinic visits. To assess
the impact on inference given the abovementioned limita-
tions of visit adherence among patients with gaps in care,
we did not censor follow-up during the first 2 years after
the first clinic visit on the basis of the pattern of scheduled
appointment attendance in this analysis.
Statistical analysis
Characteristics of included and excluded patients with nec-
essary information measured were examined and compared
using Pearson’s χ2 and Wilcoxon-Mann-Whitney tests. Un-
adjusted and inverse probability weighted modified Poisson
regression models (8, 9, 24) were used to estimate risk ratios
for the total and direct effects of African American race on
virological suppression. The total effect was defined as the
influence of African American race on virological suppres-
sion mediated through all causal pathways shown in Figure 2.
The controlled direct effect was defined as the association be-
tween African American race and virological suppression
when racial disparities in visit adherence or constancy were
lessened.
Weighted analyses accounted for sources of confounding
and selection bias related to age, calendar date, sex, CD4 cell
count, acquired immune deficiency syndrome diagnosis,
health insurance, time on ART, history of mental illness,
and history of drug or alcohol abuse at the first clinic visit,
as well as calendar date of birth, and time since last virolog-
ical success. Pattern of attendance in the 2–3 years after the
first clinic visit was also used in the weight estimation. “Pat-
tern of attendance” refers to the frequency with which a given
patient was hospitalized or attended scheduled clinic appoint-
ments, walk-in clinic visits, or scheduled urgent care or sub-
specialty appointments (e.g., dermatology). Given the few
deaths (i.e., 28), any bias related to censoring due to death
was assumed to be negligible. The proportion of the racial
disparity in virological suppression that could be eliminated
by lessening disparities in attendance on the excess relative
risk scale (i.e., proportion eliminated) was calculated on the
basis of the estimated total and direct effect(s) (25). The pro-
portion eliminated was set to 0 for all corresponding direct
effects that were further from or on the opposite side of the
null compared with the total effect.
Adjusted models estimating the total and direct effect(s),
as well as the proportion eliminated, are provided for compar-
ison. Details regarding specification and estimation of the un-
adjusted, adjusted, and weighted models are provided inWeb
Appendix 1 available at http://aje.oxfordjournals.org/. All
analyses were conducted using SAS, version 9.3, software
(SAS Institute, Inc., Cary, North Carolina).
RESULTS
The 1,481 patients in the UNC CFAR HIV clinical cohort
who were included in the analysis were followed for 1,456
person-years during the window of 2–3 years after their first
clinic visits. By the end of follow-up during the window of
2–3 years after their first clinic visits, 28 patients died, and
1,453 patients were alive. Table 1 shows the characteristics of
the 1,481 included patients along with characteristics of those
patients whowere excluded from the analysis because of the ab-
sence of RNAmeasurements 2–3 years after the first clinic visit.
Sixty-four percent of included patients were African
American, 69% were male, and 23% had previously received
a clinical acquired immune deficiency syndrome diagnosis at
the time of their first clinic visits. The median (25th percen-
tile, 75th percentile) age and CD4 count at the first clinic visit
were 40 (33, 46) years and 333 (129, 539) cells/μL, respec-
tively. During the 2 years after their first clinic visits, 36% of
patients attended all of their scheduled appointments, and
20% of patients had at least 1 attended scheduled appoint-
ment during all of the six 4-month intervals. Sixty-two per-
cent of HIV-1 RNA measurements taken 2–3 years after the
first clinic visit revealed suppressed RNA levels.
Compared with the 860 patients who were excluded from
the analysis because of the absence of RNA measurements
taken 2–3 years after the first clinic visits, patients who
were included were born earlier, less likely to be African
American, and tended to have earlier first clinic visit calendar
dates. They were older and had more advanced HIV disease
but shorter times on ART; they were also less likely to be un-
insured and to have a history of mental illness or alcohol/drug
abuse at the first clinic visit. Given that excluded patients
were likely to be less engaged in care, included patients, as
expected, also tended to have more scheduled appointments,
as well as greater visit adherence and constancy in the first 2
years after the first clinic visit.
Table 2 provides the unadjusted and weighted total effect
of African American race on virological suppression. Com-
pared with Caucasians, African Americans had an unadjusted
risk ratio for achieving virological suppression of 0.86 (95%
confidence interval (CI): 0.79, 0.92). The corresponding ad-
justed and weighted risk ratios were 0.92 (95% CI: 0.86,
0.98) and 0.91 (95% CI: 0.85, 0.98), respectively.
Table 3 shows the unadjusted and weighted effects of Af-
rican American race on virological suppression when racial
disparities in visit adherence were lessened. Compared with
Caucasians, African Americans had unadjusted risk ratios for
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achieving virological suppression ranging from 0.81 (95%
CI: 0.69, 0.95) to 1.13 (95% CI: 0.86, 1.48). The correspond-
ing adjusted and weighted risk ratios ranged from 0.84 (95%
CI: 0.74, 0.96) to 1.05 (95% CI: 0.84, 1.32) and 0.87 (95%
CI: 0.76, 0.99) to 1.12 (95% CI: 0.88, 1.44), respectively.
When interaction terms between African American race
and adherence were omitted from the unadjusted, adjusted,
and weighted models, the risk ratios for the controlled direct
effect of African American race on virological suppression
were 0.91 (95% CI: 0.84, 0.98), 0.94 (95% CI: 0.88, 1.00)
and 0.97 (95% CI: 0.91, 1.04), respectively.
Table 4 shows the unadjusted and weighted effects of Af-
rican American race on virological suppression when racial
disparities in visit constancy were lessened. Compared with
Table 1. Characteristics of HIV-Infected Patients of African American or Caucasian Race, University of North Carolina Center for AIDS Research
HIV Clinical Cohort, 1999–2012
Characteristica









Calendar dated 2001 1999, 2005 2003 2000, 2007 <0.01
Calendar date of birthd 1962 1956, 1969 1964 1958, 1972 <0.01
African American race 946 64 592 69 0.01
Age, years 40 33, 46 38 32, 45 0.01
Male sex 1,017 69 597 69 0.71
Prior clinical AIDS diagnosis 344 23 173 20 0.08
CD4 cell count, cells/μL 333 129, 539 376 187, 578 <0.01
Time on antiretroviral therapy, years 1 0, 4 1 0, 5 <0.01
Health insurance
Private 437 29 173 20
Publice 562 38 336 39 <0.01
Uninsured 482 33 351 41
History of mental illness 424 29 287 33 0.02
History of alcohol or drug abuse 399 27 333 39 <0.01
No. of scheduled appointments within
2 years after first clinic visit
8 6, 11 5 3, 8 <0.01
Proportion of scheduled appointments
attended within 2 years after first
clinic visit
0–0.732 372 25 438 51
0.733–0.874 336 23 153 18 <.01
0.875–0.999 242 16 45 5
1 531 36 224 26
Proportion of six 4-month intervals within
2 years after first clinic visit with attended
scheduled appointment
0–0.500 483 33 600 70
0.667 316 21 126 15 <.01
0.833 391 26 82 9
1 291 20 52 6
No. of RNA measurements taken 2–3 years
after first clinic visit
3 2, 4 0
Proportion of HIV-1 RNAmeasurements taken
2–3 years after first clinic visit achieving
virological suppression
1 0, 1
Abbreviations: AIDS, acquired immune deficiency syndrome; HIV, human immunodeficiency virus; HIV-1, human immunodeficiency virus type 1.
a At first clinic visit unless noted otherwise.
b No RNA measurements taken 2–3 years after first clinic visit.
c Based on Wilcoxon-Mann-Whitney or Pearson’s χ2 test.
d Expressed as year only.
e Medicaid, Medicare, or other US public insurance (e.g., AIDS Drug Assistance Program, Veterans Administration, Department of Defense for
prisoners).
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Caucasians, African Americans had unadjusted risk ratios for
achieving virological suppression ranging from 0.81 (95%
CI: 0.69, 0.95) to 0.89 (95% CI: 0.77, 1.03). The correspond-
ing adjusted and weighted risk ratios ranged from 0.89 (95%
CI: 0.78, 1.00) to 0.95 (95% CI: 0.85, 1.05) and 0.89 (95%
CI: 0.77, 1.03) to 0.93 (95% CI: 0.81, 1.07), respectively.
When interaction terms between African American race
and constancy were omitted from the unadjusted, adjusted,
Table 2. Total Effect of Race on Virological Suppression Among 946 African American Patients ComparedWith 535
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African American 1,383 1,382 2,378 2,385 0.86 0.79, 0.92 0.91 0.85, 0.98
Caucasian 1,003 938 1,477 1,410 1.00 1.00
Total 2,386 2,320 3,855 3,795
Abbreviations: AIDS, acquired immune deficiency syndrome; CI, confidence interval; HIV, human
immunodeficiency virus; HIV-1, human immunodeficiency virus type 1.
a Accounts for age, calendar date, sex, CD4 cell count, an AIDS diagnosis, health insurance, time on antiretroviral
therapy, history of mental illness, and history of drug and alcohol abuse at the first clinic visit, as well as calendar year of
birth, visit adherence and visit constancy in the first 2 years after the first clinic visit, and time since last virological
success.
Table 3. Controlled Direct Effects of African American Race on Virological SuppressionWhen Racial Disparities in Visit Adherence are Lessened
Between 946African American and 535Caucasian Patients, University of North CarolinaCenter for AIDSResearchHIVClinical Cohort, 1999–2012
Proportion of Scheduled
Appointments Attended
Within 2 Years After First
Clinic Visit by Race
HIV-1 RNA
Measurements Taken 2–
3 Years After First Clinic

















95% CI PE, %
Risk
Ratioa
95% CI PE, %
0–0.732
African American 305 454 637 897 1.13 0.86, 1.48 0 1.12 0.88, 1.44 0
Caucasian 80 109 189 261 1.00 Referent 1.00 Referent
0.733–0.874
African American 309 297 562 512 0.81 0.69, 0.95 0 0.87 0.76, 0.99 0
Caucasian 196 195 288 275 1.00 Referent 1.00 Referent
0.875–0.999
African American 225 178 384 287 0.90 0.75, 1.08 28.57 1.02 0.87, 1.19 0
Caucasian 183 137 282 212 1.00 Referent 1.00 Referent
1
African American 544 485 795 704 0.90 0.82, 1.00 28.57 0.95 0.87, 1.03 44.44
Caucasian 544 473 718 637 1.00 Referent 1.00 Referent
0–1b
African American 1,383 1,413 2,378 2,400 0.91 0.84, 0.98 35.71 0.97 0.91, 1.04 66.67
Caucasian 1,003 915 1,477 1,384 1.00 Referent 1.00 Referent
Total 2,386 2,328 3,855 3,784
Abbreviations: AIDS, acquired immune deficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; HIV-1, human
immunodeficiency virus type 1; PE, proportion eliminated.
a Accounts for age, calendar date, sex, CD4 cell count, an AIDS diagnosis, health insurance, time on antiretroviral therapy, history of mental
illness, and history of drug and alcohol abuse at the first clinic visit, as well as calendar year of birth, visit adherence and visit constancy in the
first 2 years after the first clinic visit, and time since last virological success.
b Interaction terms between African American race and visit adherence omitted.
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and weighted models, the risk ratios for the controlled direct
effect of African American race on virological suppression
were 0.85 (95% CI: 0.79, 0.92), 0.91 (95% CI: 0.86, 0.97),
and 0.92 (95% CI: 0.85, 0.98), respectively.
Significant associations between African American race
and adherence, as well as constancy, were observed when es-
timating the adherence and constancy weights. Adherence
was also significantly associated with suppression in the
weighted models that did and did not allow for an interaction
between African American race and adherence. Constancy
was not significantly associated with suppression (results in-
cluded in Web Appendix 2, Web Tables 1–4).
DISCUSSION
Among 1,481 HIV-positive patients in the UNC CFAR
HIV clinical cohort followed for 1,456 person-years, weighted
analyses showed that African Americans were less likely than
Caucasians to suppress their HIV-1 RNA. Assuming the
presence of multiplicative interaction between African Amer-
ican race and visit adherence (coefficients for interaction
terms: 0.17 (P = 0.21), −0.09 (P = 0.26), and 0.07 (P =
0.42)), assigning African American and Caucasians to be
100% adherent lessened racial disparities in virological
suppression by 44.4%. Assuming the absence of multiplica-
tive interaction between African American race and visit con-
stancy (coefficients for interaction terms: 0.04 (P = 0.67),
0.02 (P = 0.86), and 0.03 (P = 0.78)), lessening disparities
in constancy reduced racial disparities in virological suppres-
sion by 11.1%.
These weighted results suggest that interventions that
lessen disparities in adherence may be more effective in elim-
inating disparities in virological suppression than interven-
tions that lessen disparities in constancy. However, given
that gaps in care were limited to be no longer than 2 years,
the impact of lessening disparities in adherence may be over-
stated. In addition, some estimates summarizing the effect of
intervention on disparities in adherence or constancy were
imprecise, likely because of the greater amount of informa-
tion that is required to estimate direct effects.
Similar to the results of this study, prior work (4) in the
UAB 1917 Clinic Cohort indicated that lessening disparities
in adherence would reduce disparities in virological re-
sponse. However, the UAB study assumed the absence of a
multiplicative interaction between African American race
and adherence based on lack of statistical significance of
the corresponding interaction term. When a multiplicative in-
teraction between African American race and adherence was
Table 4. Controlled Direct Effects of African American Race on Virological SuppressionWhen Racial Disparities in Visit Constancy are Lessened
Between 946African American and 535Caucasian Patients, University of North CarolinaCenter for AIDSResearchHIVClinical Cohort, 1999–2012
Proportion of Six 4-month
Intervals Within 2 Years





3 Years After First Clinic

















95% CI PE, %
Risk
Ratioa
95% CI PE, %
0–0.500
African American 426 681 747 1,224 0.89 0.77, 1.03 21.43 0.93 0.81, 1.07 22.22
Caucasian 235 336 367 558 1.00 Referent 1.00 Referent
0.677
African American 235 236 432 419 0.82 0.69, 0.98 0 0.91 0.80, 1.03 0
Caucasian 245 236 371 351 1.00 Referent 1.00 Referent
0.833
African American 433 365 684 570 0.88 0.77, 1.01 14.29 0.92 0.82, 1.02 11.11
Caucasian 280 258 390 348 1.00 Referent 1.00 Referent
1
African American 289 174 515 292 0.81 0.69, 0.95 0 0.89 0.77, 1.03 0
Caucasian 243 145 349 203 1.00 Referent 1.00 Referent
0–1b
African American 1,383 1,457 2,378 2,505 0.85 0.79, 0.92 0 0.92 0.85, 0.98 11.11
Caucasian 1,003 975 1,477 1,460 1.00 Referent 1.00 Referent
Total 2,386 2,432 3,855 3,965
Abbreviations: AIDS, acquired immune deficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; HIV-1, human
immunodeficiency virus type 1; PE, proportion eliminated.
a Accounts for age, calendar date, sex, CD4 cell count, an AIDS diagnosis, health insurance, time on antiretroviral therapy, history of mental
illness, and history of drug and alcohol abuse at the first clinic visit, as well as calendar year of birth, visit adherence and visit constancy in the
first 2 years after the first clinic visit, and time since last virological success.
b Interaction terms between African American race and visit constancy omitted.
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assumed to be absent in our patient population, 66.7% of racial
disparities in virological suppression were removed when dis-
parities in adherence were lessened. Therefore, ignoring a po-
tential interaction between race and adherence because of lack
of statistical significance in this study led to an overestimation
of the impact of lessening disparities in adherence.
Furthermore, the prior UAB 1917 Clinic Cohort study ad-
justed for common causes of adherence and virological re-
sponse that are also likely influenced by race and that may
have induced selection bias or resulted in the removal of indi-
rect effects. Such selection bias or removal of indirect effects
was minimized in our weighted analysis (8, 9). Performing an
equivalent adjusted analysis yielded values for the proportion
eliminated (results not shown) that were lower in some cases
and higher in others compared with the weighted results.
The fact that visit constancy was not significantly asso-
ciated with suppression in our weighted analysis likely con-
tributed to the lack of a substantial observed reduction in
disparities in virological suppression with a reduction in dis-
parities in constancy. Prior work (7) based on combined data
from 6 academic HIV clinics in the United States found a sta-
tistically significant association between constancy and viro-
logical suppression, in which patients with greater constancy
were more likely to have suppressed HIV-1 RNA levels. The
discrepancy between this prior work and our present results
may be due to differences in study population characteristics,
in which CD4 cell counts at study entry were higher, visit ad-
herence was lower, and 4-month visit constancy was higher
in the combined study. In addition, virological suppression
was determined on the basis of a single RNA measurement
at the end of the study period rather than on multiple RNA
measurements as done in the present study.
There are limitations to the present research. The sample
sizes within levels of race and visit adherence (or visit con-
stancy) resulted in imprecise estimates in some cases and in-
creased the amount of random error. Because of changes in
the standard of care at the UNCHIV clinic, patients whowere
virologically suppressed may have been seen at the clinic less
frequently in later study years (i.e., after 2011), which might
bias results pertaining to the visit constancy measure of clinic
attendance. Although inverse probability weighting was used
to correct for measured sources of confounding and selection
bias (13, 26, 27), unmeasured potential sources of these bi-
ases related to factors such as educational level and ART ad-
herence may remain. Although methods are available to
assess the sensitivity of estimates for controlled direct effects
to unmeasured sources of confounding bias of the mediator-
outcome relationship, such methods are not applicable in the
settings explored here, inwhich the exposure determines com-
mon causes of the mediator and outcome (28). Bias can also
occur in the presence of measurement error, model misspeci-
fication, nonpositivity, or lack of consistency (29).
Despite these limitations, there are several noteworthy
strengths of this study. The use of prospective cohort data
combined with lagging helped ensure the appropriate temporal
ordering. In prior work (4), the measure of association used
was the odds ratio. When the outcome is not rare, as in this
and the prior study, the odds ratio is prone to overestimate the
risk ratio, which is the effect measure of interest, and the odds
ratio also suffers from noncollapsibility (30, 31). Here, we
directly estimated risk ratios using modified Poisson regres-
sion (24). We also used inverse probability weighting to cor-
rect for potential sources of selection and confounding bias,
which helped to avoid selection bias and the removal of indi-
rect effects (8, 9). Lastly, correct model specification was fa-
cilitated by including indicator variables for categories and
linear and quadratic terms or restricted quadratic splines for
continuous predictors.
In summary, our study found that among 1,481 HIV-
positive patients in the UNC CFAR HIV clinical cohort, Af-
rican Americans were less likely than Caucasians to have
suppressed HIV-1 RNA levels. The lessening of disparities
in visit adherence or constancy lowered disparities in virolog-
ical suppression by up to 44.4% and 11.1%, respectively.
These results suggest that interventions that lessen disparities
in visit adherence may be more effective in eliminating dis-
parities in virological suppression than interventions that
lessen disparities in visit constancy. However, given that
gaps in care were limited to be no longer than 2 years in
this study, the impact of lessening disparities in adherence
may be overstated. In addition, some estimates were impre-
cise. Future studies should replicate our analysis in other,
larger HIV clinic cohorts while allowing for interactions be-
tween race and attendance and using inverse probability
weighting to correct for potential sources of selection and
confounding bias. Future analyses should also ascertain sup-
pression at multiple RNA assessments.
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